0IL8 Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.91 |
| 52 Week Low | US$0.30 |
| Beta | 0.73 |
| 11 Month Change | 20.61% |
| 3 Month Change | -4.66% |
| 1 Year Change | -20.32% |
| 33 Year Change | -96.64% |
| 5 Year Change | n/a |
| Change since IPO | -99.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IL8 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 12.3% | 0.3% | 2.2% |
| 1Y | -20.3% | -18.3% | 8.0% |
Return vs Industry: 0IL8 underperformed the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0IL8 underperformed the UK Market which returned 8% over the past year.
Price Volatility
| 0IL8 volatility | |
|---|---|
| 0IL8 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IL8's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IL8's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 486 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. Fundamentals Summary
| 0IL8 fundamental statistics | |
|---|---|
| Market cap | US$39.84m |
| Earnings (TTM) | -US$121.79m |
| Revenue (TTM) | US$180.02m |
0.2x
P/S Ratio-0.3x
P/E RatioIs 0IL8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IL8 income statement (TTM) | |
|---|---|
| Revenue | US$180.02m |
| Cost of Revenue | US$195.17m |
| Gross Profit | -US$15.16m |
| Other Expenses | US$106.64m |
| Earnings | -US$121.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | -8.42% |
| Net Profit Margin | -67.66% |
| Debt/Equity Ratio | -45.1% |
How did 0IL8 perform over the long term?
See historical performance and comparison